Israeli telehealth startup Tyto Care is partnering with Best Buy to sell its devices for remote medical examinations to online consumers.
Founded in 2012, Tyto Care specializes in telehealth, connecting people to clinicians to provide virtual home examination and diagnosis solutions. The company’s offerings include TytoHome for patients, TytoPro for professionals, and TytoClinic for remote point-of-care testing. It also has a complete telehealth platform, analytics, built-in guidance technology, and machine learning algorithms.
Tyto Care’s TytoHome will be available exclusively on BestBuy.com for online customers and in a number of stores in Minnesota, with in-store availability coming soon in North Dakota, South Dakota, California and Ohio, the company said in a statement.
TytoHome is a handheld examination device with attachments that can examine the heart, lungs, skin, ears, throat and abdomen, as well as measure body temperature, to enable remote diagnosis of acute care situations like ear infections, sore throats, fever, cold and flu, allergies, stomach aches, upper respiratory infections, coughs, rashes and more.
The device enables users to perform comprehensive medical exams and send information to a primary care provider for a diagnosis. It sells for $299.99.
LiveHealth Online, an American telehealth platform powered by American Well, will be the healthcare provider for users who purchase TytoHome at BestBuy.com and reside outside of Minnesota, Iowa, North Dakota or South Dakota. Through LiveHealth Online, select employers can offer the service to their employees and provide them with coupons to purchase TytoHome at Best Buy, Tyto Care said.
Tyto Care co-founder and CEO Dedi Gilad said the company was “excited to partner with Best Buy, LiveHealth Online, American Well and regional health systems to extend our on-demand telehealth platform across the US, enhancing primary care delivery.”
“Tyto Care is combining increased convenience and accessibility with the power of a trusted retailer, health care providers, insurers and employers to deliver consumers the best that telehealth has to offer.”
Earlier this year, Tyto Care secured an additional $9 million in funding from strategic investors including Sanford Health, Japan’s Itochu, and China’s Shenzhen Capital Group, to close out a $33.5 million Series C round.
Tyto Care has FDA clearance and launched its products in the US in 2017. It also has a CE mark for Europe and gained Health Canada approval in 2018. In recent years, the company has gained significant traction with major health systems, telehealth companies, large private practices and employers.